R Michael Lawrence

USPTO Granted Patents = 61 (Patent Applications = 4)

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 16 (Patent Applications = 12)

Average Co-Inventor Count = 7.2

ph-index = 12

Forward Citations = 835(Granted Patents)

Forward Citations (Not Self Cited) = 790(Oct 12, 2025)

Inventors with similar research interests:

Location History:

Yardley, NJ (US) (2018 - 2020)
Yardley, PA (US) (1995 - 2024)

Company Filing History:

55 out of 3,681

Bristol-myers Squibb Compnay

patents

6 out of 183

Universitéde Montreal

patents

1 out of 3

Britsol-myers Squibb Company

patents

4. 5 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2024

Loading Chart...

61 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12168655 - Apelin receptor agonists and methods of use (2024-12-17),

2. 12097242 - Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides (2024-09-24),

3. 12097241 - Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides (2024-09-24),

4. 12084452 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation (2024-09-10),

5. 11498903 - 2-(1,1'-biphenyl)-1H-benzodimidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases (2022-11-15),

6. 11390616 - Apelin receptor agonists and methods of use (2022-07-19),

7. 11364281 - Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof (2022-06-21),

8. 11185570 - Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides (2021-11-30),

9. 10966967 - Aryl dihydropyridinones and piperidinone MGAT2 inhibitors (2021-04-06),

10. 10822343 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation (2020-11-03),

11. 10695328 - Aryl dihydropyridinones and piperidinone MGAT2 inhibitors (2020-06-30),

12. 10669261 - Heteroarylhydroxypyrimidinones as agonists of the APJ receptor (2020-06-02),

13. 10590113 - 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists (2020-03-17),

14. 10428077 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation (2019-10-01),

15. 10392347 - 2,4-dihydroxy-nicotinamides as APJ agonists (2019-08-27),

Title: The Innovative Journey of R Michael Lawrence

Introduction: R Michael Lawrence, a distinguished inventor hailing from Yardley, PA (US), has made significant contributions to the field of technology through his groundbreaking innovations.

Latest Patents: R Michael Lawrence holds several patents in various technological domains, showcasing his versatility and ingenuity in inventing cutting-edge solutions for complex problems.

Career Highlights: With a career spanning over two decades, R Michael Lawrence has consistently pushed the boundaries of technological advancement. His work has not only revolutionized industries but has also improved the quality of life for many individuals around the world.

Collaborations: Throughout his career, R Michael Lawrence has collaborated with leading tech companies, research institutions, and universities to bring his inventions to life. These collaborations have been instrumental in the successful development and commercialization of his innovative ideas.

Conclusion: R Michael Lawrence's passion for innovation, coupled with his dedication to solving real-world challenges, has established him as a prominent figure in the world of inventors. His relentless pursuit of excellence continues to inspire the next generation of innovators to push the limits of what is possible.

This text is generated by artificial intelligence and may not be accurate.